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Introduction:Cerebrospinal fluid biomarkers increasingly inform the causes of demen-
tia and may provide objective markers of disease progression. There is a need to deci-
pher participant and procedural factors that promote participation in studies incorpo-
rating longitudinal biomarker measures.
Methods: Participant and procedural factors associated with participation in longitudi-
nal biomarker studieswere determined in individuals enrolled in studies ofmemory and
aging at the Knight Alzheimer Disease Research Center (Saint Louis, MO, USA).
Results: Complications were encountered following 331 of 1484 lumbar punctures
(22.3%; LPs), affecting 280 of 929 participants (30.1%); in >95% complications were
minor. Three hundred fifteen of 679 eligible participants (46.4%) completed multiple
LPs. Younger age (odds ratio [OR] 2.08 per decade [95% confidence interval (CI) 1.61–
2.94]), normal cognition (OR 21.4 [2.85–160.1]), and the absence of heart disease (OR
2.0 [1.01–3.85]) or seizures at study entry identified participants with increased odds
of completing three or more LPs.
Discussion: Factors influencing participationmay be leveraged to improve recruitment
and retention within observational and therapeutic studies requiring serial LPs.
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1 BACKGROUND
Biomarkers are used increasingly to determine the cause of
dementia,1–4 define the biochemical changes that influence rates
of disease progression,5,6 and identify individuals at high risk of
developing dementia who may benefit from therapeutic interventions
designed to delay or prevent cognitive impairment.7 Cerebrospinal
fluid (CSF) biomarkers are ideal for this purpose, as CSF is sensitive
to the early changes associated with the most common cause of
dementia, Alzheimer’s disease (AD)8; can be analyzed simultaneously
for multiple analytes that directly reflect biochemical changes within
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the central nervous system; and can be safely and efficiently sampled
from individuals with all levels of cognitive impairment,9,10 informing
the dynamic relationship between biomarkers and symptomatic
expression of disease.11,12
Despite the high value placed on CSF in research,13 participants
express low enthusiasm for participation in studies requiring lumbar
puncture (LP).14 Several factors contribute to this reticence, including
concerns regarding the safety of the procedure.14,15 Although LP is
typically safe, complications are encountered in research and clinical
settings. Most commonly, these complications includemild self-limited
low-back pain or headache, with medical intervention limited to
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the <5% of participants who require an autologous blood patch for
the treatment of post-dural puncture headache.15–20 Prior research
in this area has shown that fearfulness of LP is reduced in participants
who have previously completed a successful LP,14 suggesting that
these participants should be more willing to participate in subsequent
LPs. However, retention within studies requiring serial LPs remains
challenging.
There is a need to promote participant enrollment and engage-
ment within research studies requiring serial LPs, yet the factors that
influence longitudinal participation are largely unknown. Recognizing
this, we evaluated the participant and procedural factors that asso-
ciated with serial LP completion by community-dwelling participants
enrolled within longitudinal studies of memory and aging at the Knight
Alzheimer Disease Research Center (ADRC; Washington University
School of Medicine; Saint Louis, MO, USA). Emphasis was placed on
identifying potentiallymodifiable factors that could be targeted to pro-
mote retention in longitudinal research studies, including prior history
of LP complications.
2 METHODS
2.1 Standard protocol approvals, registrations,
and patient consents
This nested-cohort study included data from prospectively evaluated
community-dwelling individuals enrolled within longitudinal studies of
memory and aging at the Knight ADRC between January 2004 and
April 2018. Eligible participants completed at least one clinical assess-
ment and research LP, and consented to the use of information and
CSF specimens for research purposes. Study procedures and policies
were approved by theWashingtonUniversity School ofMedicine Insti-
tutional Review Board.
2.2 Clinical assessments and research lumbar
punctures
Beginning in 2004, newly enrolled research participants agreed in
principle to undergo an LP for research purposes at study entry and
every 3 years thereafter. Exceptions were made for African Amer-
ican participants, with the intent to improve representation within
research, irrespective of opportunities tomeasure CSF biomarkers.
Prior to undergoing an LP, participants were evaluated by expe-
rienced clinicians using semi-structured interviews with both the
participant and a knowledgeable collateral source, and a detailed
neurologic examination of the participant.21 When appropriate,
diagnoses of dementia were rendered by study clinicians, integrating
results from the clinical assessment and bedsidemeasures of cognitive
function, referencing established diagnostic criteria.22,23 The severity
of cognitive impairment was staged using the global Clinical Dementia
Rating (CDR) scale.24 Participants with moderate or severe dementia
(CDR ≥2) were not asked to undergo serial LPs and were excluded
RESEARCH INCONTEXT
1. Systematic review: The authors reviewed the literature
using traditional sources (eg, PubMed). Despite increas-
ing interest in the use of longitudinal biomarkermeasures
in dementia research,11–13 no studies considered how to
promote engagement within studies incorporating serial
cerebrospinal fluid (CSF) measures.
2. Interpretation: Age, cognitive status, and health history
at study entry independently influenced odds of partic-
ipation in serial lumbar punctures (LPs) in community-
dwelling older adults enrolled in prospective studies of
memory and aging. This information can be leveraged to
promote recruitment of individuals who are more likely
to agree to longitudinal CSF sampling, and to enhance
retentionof enrolledparticipantswhoare likely todecline
requests for subsequent LPs.
3. Future directions: Strategies are needed to reduce
burden associated with participation in longitudinal
biomarker research. Particular attention should be paid
to the needs of older, cognitively impaired participants
withmedical comorbidities.
from longitudinal analyses. Participants prescribed dual antiplatelet
therapies were counseled to hold one anti-platelet agent 7 days before
their planned LP. If their prescribing physician deemed this unsafe,
an LP was not scheduled and they were excluded from longitudinal
analyses. Similarly, LPs were not performed in participants with other
known contraindication (eg, space-occupying cerebral lesion, ongoing
anticoagulant therapy25), and they were excluded from longitudinal
analyses.
On the day of the LP, participants were informed of the rationale
for the LP and associated risks. Participants were counseled to avoid
strenuous activity for 24 hours following the procedure and to hydrate
with clear fluids and caffeinated beverages if desired. All participants
were instructed to notify study personnel if concerning symptoms
or side effects developed following the LP, and were reassured that
access to a blood patch would be provided by study-affiliated physi-
cians if required to treat post-dural puncture headache. LPs were
completed by experienced neurologists using established protocols
in consented individuals.26 Briefly, LPs were performed in the early
morning (between 0730 and 0900 hours) on fasted participants.
Unless contraindicated, participants were seated in a massage chair,
and local analgesia accomplished with 1% lidocaine injected subcu-
taneously via a 25-gauge needle. CSF was sampled using a 22-gauge
atraumatic (“non-cutting”) Sprotte needle, advanced between the
L3/L4 or L4/L5 vertebrae. If CSF could not be accessed using standard
techniques, the operating clinician could reattempt the procedurewith
the participant in the lateral decubitus position. Conventional (“cut-
ting”) spinal needles (22-gauge) were available upon request by the
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operating clinician. Deviances from standard procedures and intrapro-
cedural LP complicationswere documented prospectively by the study
coordinator.
Following the LP, participants were provided with breakfast and
observed for 1 hour before discharge home. Participants were encour-
aged to lie supine throughout the observation period, although this
was not strictly enforced. All participants were reached by telephone
within 24 hours and queried concerning post-procedural side effects.
Additional follow-up calls established the natural history of post-LP
complications when necessary. All complaints and concerns were
reviewed with study physicians and patients were recommendations
for treatment providedwhen appropriate. Complications that resolved
within 24hourswith rest andover-the-counter analgesicswere graded
as mild (eg, back pain at the site of needle insertion). Moderate compli-
cations included those that persisted beyond 24 hours. Complications
requiring medical evaluation or physician-directed intervention
(namely a blood patch) were graded as severe. Autologous blood
patch was offered to any patient who fulfilled International Classi-
fication of Headache Disorders Criteria III for post-dural puncture
headache,27 and in whom headache persisted for >24 hours despite
implementation of conservative management strategies (rest, hydra-
tion, and analgesia). Autologous blood patches were undertaken by
experienced anesthesiologists, targeting the general proximity of the
prior LP.
2.3 Data analysis
Demographic, clinical, and LP data were available from all participants
who completed one or more research LPs. Additional data concerning
apolipoprotein epsilon (APOE𝜀) genotype and AD biomarkers (CSF
levels of amyloid 𝛽 [A𝛽]40–42, total-tau, and phosphorylated-tau;
measured using the Elecsys assay as previously reported28) were
available from a majority of participants. Participants who were eligi-
ble to complete two or more consecutive LPs were defined as “serial
completers.”
Demographic and clinical details were summarized using descrip-
tive statistics and the frequency of LP complications determined
across participants. Demographic and participant and procedural
factors associated with post-LP complications and serial completion
of LP studies were evaluated using the chi-square or Fisher exact tests
for categorical variables and Student t (independent variables) for
continuous variables. Variables implicated as potential contributors to
post-LP complications or serial completion of LP studies on univariate
analyzes (P < 0.05) were further evaluated using multivariable logistic
regression (forced entry), allowing the effect of variables on the
outcome of interest to be quantified while adjusting for confounding
variables. Variables were excluded if data were missing from >10%
of eligible individuals. Model explanatory power was assessed using
the c-statistic (area under the receiver operating characteristic [ROC]
curve). Statistical analyses were conducted using SPSS Statistics
(IBM Corp., Version 24.0. Armonk, NY). Statistical significance was
established at P< 0.05.
TABLE 1 Participant characteristics at the time of first lumbar
puncture
Participant characteristics Participants (n= 929)
Age, mean (±SD), years 68.7 (9.3)
Sex, female, n (%) 492 (53.0)
Race, n (%)
Non-Hispanic white 834 (89.8)
African American 86 (9.3)
Other 9 (1.0)
Education, mean (±SD), years 15.9 (2.7)
Cognitive status, n (%)
Cognitively normal 690 (74.3)
Symptomatic Alzheimer’s disease 163 (17.5)
Other dementia 76 (8.2)
APOE𝜀4 carrier, n (%) 355/876 (40.5)
APOE, apolipoprotein; SD, standard deviation.
2.4 Data availability
Study data are available to qualified investigators upon approval of




Between January 2004 andMay 2018, a total of 929 participants com-
pleted 1484 LPs. Participant characteristics at the time of their first
LP are detailed in Table 1. Participants were well educated, with ages
spanning mid-to-late life (range, 42.7- to 99.4-years old). The majority
of participants were non-Hispanic white and cognitively normal (CDR
0), and reflected the characteristics of the surrounding community.
AD was the most common cause of cognitive impairment (163/239,
68.2%), with most affected participants exhibiting very mild (CDR 0.5;
n= 111, 68.1%) ormild dementia (CDR1; n= 48, 29.4%) at study entry.
Participants with moderate severity AD dementia (CDR 2; n = 4, 2.5%)
at study entry were not asked to complete subsequent LPs.
3.2 Lumbar puncture complications
Complications were reported following 331 LPs (22.3%), affecting 280
(30.1%) distinct participants (Table 2).More than 95%of complications
resolved within 24 hours without medical intervention and were
deemed minor. Severe complications requiring medical intervention
were limited to the 38 participants (2.6%) with unremitting post-dural
puncture headaches who required autologous blood patches. Univari-
ate comparisons suggested that complications were overrepresented
in younger, female, and cognitively normal participants with a history
4 of 9 DAY ET AL.
TABLE 2 Complications reported following 1484 lumbar
punctures





Back pain 141 (9.5)
Vasovagal response 56 (3.8)
Syncope 26 (1.8)
aMild headache = self-resolving without medical intervention within
24 hours;moderate headache= lasting>24hours; severe= requiring blood
patch or hospitalization.
of dyslipidemia, cardiovascular disease, or prior LP complication, and
normal A𝛽42 levels. Complications were also associated with the use
of a non-Sprotte (cutting needle) and the volume of CSF withdrawn.
The mean difference in CSF volume between participants with and
without a complication was <1 cc, and was deemed unlikely to be
clinically relevant. Younger age, female sex, cognitively normal status,
lower body mass index, and fewer years of operator experience
were associated with severe complications (Table 3). When these
variables were considered together via multivariable logistic regres-
sion, younger age, female sex, cognitive normal status, and use of
a traumatic needle independently predicted an increased odds of a
post-LP complication (n = 1360). Younger age, lower body mass index
[BMI], and fewer years of clinician experience performing LPs were
independent predictors of severe complications (n = 1386; Appendix
A). In general, the multivariable model demonstrated a modest ability
to identify participantswhowere likely to experience any complication
(c-statistic, any complication = 0.65 [95% CI 0.61-0.68], P < 0.001),
suggesting that unmeasured participant or procedural risk factors
also influenced LP complications. By contrast, the model accurately
identified participants likely to experience a severe complication
(c-statistic, severe complication= 0.84 [95%CI 0.79-0.90], P< 0.001).
3.3 Participation in serial lumbar punctures
Rates of participation in serial LPs among eligible participants declined
following the first and second LPs before plateauing (Figure 1).
TABLE 3 Association between participant and procedural factors and post-LP complications
Any complication, n= 331 Severe complication, n= 38
Measured variables Present Absent P value Present Absent P value
Participant-specific factors at time of first LP
Age, mean (±SD), years 65.8 (8.9) 69.2 (8.9) <0.001 60.5 (9.7) 68.7 (8.9) <0.001
Female sex, n (%) 218 (65.9) 610 (52.9) <0.001 28 (73.7) 800 (55.3) 0.02
Education, mean (±SD), years 16.0 (2.4) 16.0 (2.7) 0.94 16.2 (2.4) 16.0 (2.6) 0.60
Non-Hispanic white, n (%) 298 (90.0) 1037 (89.9) 0.96 37 (97.3) 1298 (89.8) 0.17a
Cognitively normal, n (%) 294 (88.9) 919 (79.7) <0.001 36 (94.7) 1177 (81.4) 0.04
LowCSF A𝛽42, n (%) 130 (39.4) 526 (46.1) 0.03 16 (42.1) 640 (44.6) 0.76
BMI, mean (±SD), kg/m2 27.5 (5.9) 27.9 (5.4) 0.23 23.5 (3.3) 27.9 (5.5) <0.001
APOEɛ4 carrier, n (%) 112 (35.9) 427 (39.3) 0.27 15 (41.7) 524 (38.5) 0.70
Cardiovascular disease, n (%) 60 (18.1) 283 (24.5) 0.02 5 (13.2) 338 (23.4) 0.14
Cerebrovascular disease, n (%)b 11 (4.4) 42 (4.8) 0.81 2 (7.1) 51 (4.6) 0.38a
Dyslipidemia, n (%) 125 (40.1) 541 (51.1) 0.001 9 (32.0) 657 (48.9) 0.08
Diabetes, n (%) 32 (9.7) 98 (8.5) 0.51 0 130 (9.0) 0.07a
Hypertension, n (%) 137 (43.8) 485 (45.2) 0.66 9 (30.0) 613 (45.2) 0.10
Mood disorder, n (%) 70 (21.1) 223 (19.3) 0.47 4 (10.5) 289 (20.0) 0.15
Seizures, n (%) 6 (2.0) 27 (2.6) 0.55 1 (2.6) 32 (2.4) 0.61a
Smoking history, n (%)b 125 (47.9) 428 (44.9) 0.39 13 (38.2) 540 (45.8) 0.39
Thyroid disease, n (%) 51 (15.4) 203 (17.6) 0.35 6 (15.8) 248 (17.2) 0.83
Procedure-specific factors
Operator experience, mean (±SD), years 4.5 (4.1) 4.4 (4.1) 0.56 2.6 (2.2) 4.4 (4.1) 0.006
Any prior LP complication, n (%) 331 (15.4) 124 (10.8) 0.02 1 (2.6) 174 (12.0) 0.12
Traumatic needle, n (%) 9 (2.7) 11 (1.0) 0.03a 0 20 (1.4) >0.99a
Lateral decubitus position, n (%) 15 (4.5) 37 (3.2) 0.25 0 52 (3.6) 0.64a
Volume of CSF collected, mean (±SD), mLb 24.3 (2.6) 25.0 (2.3) 0.001 25.4 (2.5) 24.8 (2.4) 0.35
aFisher exact test.
bDatamissing for>10% of events.
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F IGURE 1 Rates of participation in serial lumbar punctures (LPs) at study entry and every 3 years thereafter. Participants eligible to complete
serial LPs (black) are shown alongside of those who successfully completed serial LPs (gray). Rates of completion (solid line) demonstrate that
participation rates declined from the first (study entry) to the third LP (year 6), before plateauing
The participant and procedural factors associated with serial LP
completion are detailed in Table 4. Younger age, female sex, greater
years of education, cognitively normal status, normal CSF A𝛽42 levels,
and the absence of cardiovascular disease, dyslipidemia, hypertension,
or prior history of LP complication were overrepresented in partici-
pants completing twoormore LPs. Similar factorswere associatedwith
completion of three ormore LPs, with the exception of a history of dys-
lipidemia and prior LP complication (no longer associated) and seizures
(nowassociated).Multivariable logistic regression established younger
age, and cognitively normal status as independent predictors of serial
completers (≥2 LPs; data from 678 eligible participants were included
in themodel). Unexpectedly, abnormally lowCSFA𝛽42 levels were also
associated with greater odds of completing two or more LPs, when
accounting for the effects of other variables, including cognitive status
(Figure 2, Panel A). Young, cognitively normal participants without a
prior history of heart disease exhibited the greatest odds of completing
three ormore LPs (data from 406 eligible participants were included in
themodel). Noparticipantswith a reported seizuredisorder completed
≥3 LPs (Figure 2; Appendix B). Model statistics confirmed fair ability
of the model to predict serial completion (c-statistic, ≥2 LPs = 0.79
[95% CI 0.76-0.83], P < 0.001; c-statistic, ≥3 LPs = 0.78 [95% CI
0.73-0.82], P < 0.001). Of interest, after controlling for the effect of
other variables, a prior history of LP complication (including severe
complication) did not deter participants from participating in serial
LPs.
4 DISCUSSION
Complications requiring medical intervention occurred following 2.6%
of 1484 LPs performed in 929 older community-dwelling participants
enrolled in longitudinal studies of memory and aging at our center.
Younger age, lower BMI, and fewer years of clinician experience
performing LPs were all associated with greater odds of a severe com-
plication (namely, post-dural puncture headache). Other complications
occurred following an additional 19.7% of LPs. Most of the compli-
cations were mild and self-resolving and did not influence odds of
participation in a subsequent LP. Only younger age, normal cognition,
and the absence of heart disease or history of seizure disorder at study
entry increased the odds of participation in serial (≥3) LPs.
Rates and types of post-LP complications in community-dwelling
volunteers in our studies were consistent with those reported in
cohorts including patients for whom mild self-limiting side effects
occurred following 11% to 30% of LPs, and more serious complica-
tions requiring intervention (eg, blood patch for post-dural puncture
headache) were encountered in <5%.15–20 Similar factors predis-
posing to post-LP complications were identified in the largest of
these cohorts—a multi-center study performing LPs in 3456 unique
patients at 23 European memory clinics.17 Age <65 years, absence
of a dementia diagnosis, and use of a traumatic (cutting) needle were
also associated with increased risk of post-dural puncture headache
in this multicenter study. Uniquely, this study also identified a prior
history of headache, patient-expressed fears of post-LP complications,
use of larger bore needle (<22 gauge), and upright positioning as
key participant and procedural risk factors for moderate-to-severe
post-dural puncture headaches.17 Female sex was not associated with
any increased risk of complications,17 contrasting findings in this and
other cohorts.29,30 Taken together, this information can be leveraged
to improve informed consent, providing individual participants with
a realistic expectation of procedural risks. By identifying participants
at the greatest risk of moderate-to-severe complications, it may also
be possible to implement risk-reduction strategies, including the use
of smaller gauge needles and lateral decubitus positioning in select
individuals.15,17,18
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TABLE 4 Association between participant and procedural factors and completion of serial LPs
Eligible to complete≥2 consecutive LPs (n= 679) Eligible to complete≥3 consecutive LPs (n= 432)
Measured variables Completed Not completed P value Completed Not completed P value
Participant-specific factors at time of first LP
Age, mean (±SD), years 65.3 (8.0) 72.0 (7.9) <0.001 61.7 (8.6) 69.0 (9.3) <0.001
Female sex, n (%) 184 (58.4) 178 (48.9) 0.01 78 (61.9) 143 (50.3) 0.03
Education, mean (±SD), years 16.2 (2.5) 15.6 (2.9) 0.01 16.1 (2.4) 15.7 (2.8) 0.15
Non-Hispanic white, n (%) 280 (88.9) 329 (90.4) 0.52 114 (90.5) 258 (90.8) 0.91
Cognitively normal, n (%) 300 (95.2) 224 (61.5) <0.001 125 (99.2) 222 (78.2) <0.001
LowCSF A𝛽 , n (%) 97 (30.9) 176 (48.4) <0.001 31 (24.8) 112 (39.4) 0.004
BMI, mean (±SD), kg/m2 27.9 (5.7) 27.3 (4.9) 0.14 28.0 (4.8) 27.7 (5.3) 0.60
APOEɛ4 carrier, n (%) 106 (35.9) 144 (42.9) 0.08 41 (34.5) 99 (38.4) 0.46
Cardiovascular disease, n (%) 53 (16.8) 114 (0.31) <0.001 14 (11.1) 70 (24.7) 0.002
Cerebrovascular disease, n (%)b 6 (2.3) 18 (5.6) 0.05 3 (3.2) 10 (4.1) >0.99a
Dyslipidemia, n (%)b 103 (39.8) 165 (51.6) 0.005 40 (42.1) 117 (49.4) 0.23
Diabetes, n (%) 25 (7.9) 31 (8.5) 0.78 9 (7.1) 21 (7.4) 0.93
Hypertension, n (%)b 103 (39.3) 157 (47.9) 0.04 33 (34.4) 113 (46.1) 0.049
Mood disorder, n (%) 57 (18.1) 80 (22.0) 0.21 17 (13.5) 54 (19.0) 0.17
Seizures, n (%) 5 (1.6) 14 (3.9) 0.07 0 10 (3.6) 0.03
Smoking history, n (%)b 136 (43.9) 173 (48.7) 0.24 59 (46.8) 128 (46.7) 0.98
Thyroid disease, n (%) 46 (14.6) 49 (13.5) 0.69 19 (15.0) 38 (13.4) 0.65
Procedure-specific factors
Any LP complication, n (%) 73 (23.2) 62 (17.0) 0.046 25 (19.8) 60 (21.1) 0.77
Severe LP complication, n (%) 11 (3.5) 11 (3.0) 0.73 6 (4.8) 13 (4.6) 0.94
aFisher exact test.
bDatamissing for>10% of events.
Clinician experience performing LPs was inversely correlated with
the odds of severe LP complications in our study. This finding adds to
a growing body of literature reporting positive correlations between
clinician experience and patient confidence and operator stress and
procedural complications,31 and suggests that clinician experience (or
lack thereof) may contribute to the wide variability in complication
rates reported across studies.15–20 Accordingly, clinician experience
may represent an important modifiable procedural risk factor, raising
the possibility that additional training aimed at reducing clinician
stress and promoting familiarity with the procedure may reduce
procedural complications while increasing participant confidence and
comfort.
Standard procedures in our study included the use of a 22-gauge
atraumatic needle in seated (upright) volunteers. These differences
may have contributed to the higher incidence of complications requir-
ing medical intervention in our cohort (2.6% [38/1484]) versus those
reported in another large study (1.0% [33/3456]17). However, this dif-
ference also may reflect the low threshold for offering and performing
blood patch in volunteers in our study, owing to the ease of accessibil-
ity of blood patches at our center, history of excellent response in par-
ticipants, and desire to minimize duration of symptoms in community-
dwelling volunteers. Indeed, blood patcheswere performed in 38 of 41
(93%) of participants with post-LP headache lasting >24 hours in our
study, but only 11 of 470 (2.3%) of patients in the Duit et al. cohort.17
No participants in our study required hospitalization for management
of post-LP complications (vs 23 [0.7%] patients17). It is unclearwhether
early use of autologous blood patches maymitigate symptom duration
and the need for additional medical intervention or hospitalization.
Uniquely, this study identified independent predictors of partici-
pation in serial LPs, including younger age, absence of cardiovascular
disease or seizure disorder, and normal cognition at study entry.
Although the majority of these factors are associated with longevity,
their selection was not attributable to a survival effect, noting that
only participants who were eligible to complete a diagnostic LP were
included in the longitudinal analyses (ie, participants who died, with-
drew from the study, or developed an uncorrectable contraindication
for LP25 were excluded). Thus, it is more likely that advancing age,
declining cognition, and the presence of comorbidities associated
with frequent medication use (including antiplatelet agents) identified
participants who were most likely to perceive LPs as burdensome.
This information can be used to promote recruitment of individuals
who are most likely to agree to longitudinal CSF sampling, while
focusing retention efforts on participants who are at-risk of declining
future LPs. Such efforts could include targeted educational campaigns
emphasizing the importance of longitudinal biomarker measures in
aging research (eg, see 32–34), in combinationwith practical initiatives
aimed at reducing burden for aging cognitively impaired participants
with increasingmedical comorbidities.
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F IGURE 2 Factors influencing participation in serial lumbar punctures (LPs). Odds ratios± 95% confidence intervals are shown for factors
associated with participation in≥2 (Panel A) and≥3 consecutive LPs. No participant with a prior history of seizure disorder completed≥3 LPs (OR
≈ 0; not shown)
This nested cohort study leveraged data from a large cohort of par-
ticipants enrolled in studies of memory and aging at a single center.
Although prospective collection of information is a strength, the par-
ent studies were not designed to measure participant and procedural
factors associated with participation in biomarker substudies. Accord-
ingly, data were not available concerning several factors that may
have influenced complications and longitudinal participation. Partici-
pant perceptions concerning LPs are one such factor, with participant
anxiety and fear known to associate with complications and reticence
to participate in LPs.15,17,18,20 In addition, it is unknown whether rapid
access to blood patches—a unique feature of this study—influenced
participation in serial LPs. Reassurance of access to blood patches
for the treatment of post-dural puncture headaches may represent
onemeans of assuaging participant concerns regarding diagnostic LPs,
althoughwe acknowledge that the expertise and resources required to
support this initiativemaynot be readily transferable to other research
and clinical centers. As interest in and applications of longitudinal
biomarkers continues to expand, it will become increasingly important
to understand and protect against factors that increase LP complica-
tions and compromise participation in research incorporating serial
CSF sampling, including both observational and clinical/therapeutic
studies.
5 CONCLUSIONS
Younger, cognitively normal participants without known heart disease
or seizure disorder at study entry were more likely to participate in
studies requiring serial CSF sampling. Prior history of LP complications
did not influence participation in LP studies when controlling for the
effect of other variables. Knowledge of the participant and procedural
specific factors that influence participation in studies requiring serial
CSF sampling may be leveraged to promote recruitment and retention
within studies requiring serial LPs.
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SUPPORTING INFORMATION
Additional supporting informationmay be found online in the Support-
ing Information section at the end of the article.
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